Advertisement

Table of Contents

In This Issue

  • In This Issue
    In This Issue
    Cancer Discov January 1 2018 8 (1) 1-3; DOI:10.1158/2159-8290.CD-ITI8-1

In the Spotlight

Review

Research Briefs

  • Research Briefs | AuthorChoice
    Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma
    Eirini Pectasides, Matthew D. Stachler, Sarah Derks, Yang Liu, Steven Maron, Mirazul Islam, Lindsay Alpert, Heewon Kwak, Hedy Kindler, Blase Polite, Manish R. Sharma, Kenisha Allen, Emily O'Day, Samantha Lomnicki, Melissa Maranto, Rajani Kanteti, Carrie Fitzpatrick, Christopher Weber, Namrata Setia, Shu-Yuan Xiao, John Hart, Rebecca J. Nagy, Kyoung-Mee Kim, Min-Gew Choi, Byung-Hoon Min, Katie S. Nason, Lea O'Keefe, Masayuki Watanabe, Hideo Baba, Rick Lanman, Agoston T. Agoston, David J. Oh, Andrew Dunford, Aaron R. Thorner, Matthew D. Ducar, Bruce M. Wollison, Haley A. Coleman, Yuan Ji, Mitchell C. Posner, Kevin Roggin, Kiran Turaga, Paul Chang, Kyle Hogarth, Uzma Siddiqui, Andres Gelrud, Gavin Ha, Samuel S. Freeman, Justin Rhoades, Sarah Reed, Greg Gydush, Denisse Rotem, Jon Davison, Yu Imamura, Viktor Adalsteinsson, Jeeyun Lee, Adam J. Bass and Daniel V. Catenacci
    Cancer Discov January 1 2018 8 (1) 37-48; DOI:10.1158/2159-8290.CD-17-0395

    Heterogeneity of actionable genomic alterations among primary and metastatic lesions suggests that biomarker profiling of a single primary tumor site may limit the success of targeted therapy in gastroesophageal adenocarcinoma.

  • Research Briefs | AuthorChoice
    Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer
    Yelena Y. Janjigian, Francisco Sanchez-Vega, Philip Jonsson, Walid K. Chatila, Jaclyn F. Hechtman, Geoffrey Y. Ku, Jamie C. Riches, Yaelle Tuvy, Ritika Kundra, Nancy Bouvier, Efsevia Vakiani, Jianjiong Gao, Zachary J. Heins, Benjamin E. Gross, David P. Kelsen, Liying Zhang, Vivian E. Strong, Mark Schattner, Hans Gerdes, Daniel G. Coit, Manjit Bains, Zsofia K. Stadler, Valerie W. Rusch, David R. Jones, Daniela Molena, Jinru Shia, Mark E. Robson, Marinela Capanu, Sumit Middha, Ahmet Zehir, David M. Hyman, Maurizio Scaltriti, Marc Ladanyi, Neal Rosen, David H. Ilson, Michael F. Berger, Laura Tang, Barry S. Taylor, David B. Solit and Nikolaus Schultz
    Cancer Discov January 1 2018 8 (1) 49-58; DOI:10.1158/2159-8290.CD-17-0787

    Prospective genomic profiling of patients with esophagogastric cancer identifies predictive biomarkers of sensitivity and resistance to trastuzumab and immune checkpoint inhibitors.

  • Research Briefs
    Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression
    Maria Rusan, Kapsok Li, Yvonne Li, Camilla L. Christensen, Brian J. Abraham, Nicholas Kwiatkowski, Kevin A. Buczkowski, Bruno Bockorny, Ting Chen, Shuai Li, Kevin Rhee, Haikuo Zhang, Wankun Chen, Hideki Terai, Tiffany Tavares, Alan L. Leggett, Tianxia Li, Yichen Wang, Tinghu Zhang, Tae-Jung Kim, Sook-Hee Hong, Neermala Poudel-Neupane, Michael Silkes, Tenny Mudianto, Li Tan, Takeshi Shimamura, Matthew Meyerson, Adam J. Bass, Hideo Watanabe, Nathanael S. Gray, Richard A. Young, Kwok-Kin Wong and Peter S. Hammerman
    Cancer Discov January 1 2018 8 (1) 59-73; DOI:10.1158/2159-8290.CD-17-0461

    Blocking RNA polymerase II–mediated transcription with a CDK7/CDK12 inhibitor broadly enhances the efficacy of targeted therapies by suppressing transcriptional responses associated with establishment of a drug-tolerant state.

Research Articles

  • Research Articles | AuthorChoice
    Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma
    Aayoung Hong, Gatien Moriceau, Lu Sun, Shirley Lomeli, Marco Piva, Robert Damoiseaux, Sheri L. Holmen, Norman E. Sharpless, Willy Hugo and Roger S. Lo
    Cancer Discov January 1 2018 8 (1) 74-93; DOI:10.1158/2159-8290.CD-17-0682

    Treatment discontinuation sensitizes MAPK inhibitor–resistant melanoma to PARP inhibition and augments a cell death–predominant drug-addiction phenotype.

  • Research Articles
    Conversion of PRPS Hexamer to Monomer by AMPK-Mediated Phosphorylation Inhibits Nucleotide Synthesis in Response to Energy Stress
    Xu Qian, Xinjian Li, Lin Tan, Jong-Ho Lee, Yan Xia, Qingsong Cai, Yanhua Zheng, Hongxia Wang, Philip L. Lorenzi and Zhimin Lu
    Cancer Discov January 1 2018 8 (1) 94-107; DOI:10.1158/2159-8290.CD-17-0712

    Inhibition of phosphoribosyl pyrophosphate synthetase (PRPS) by AMPK under glucose-deprived or hypoxic conditions maintains homeostasis and promotes tumor cell survival.

  • Research Articles | AuthorChoice
    Somatic Superenhancer Duplications and Hotspot Mutations Lead to Oncogenic Activation of the KLF5 Transcription Factor
    Xiaoyang Zhang, Peter S. Choi, Joshua M. Francis, Galen F. Gao, Joshua D. Campbell, Aruna Ramachandran, Yoichiro Mitsuishi, Gavin Ha, Juliann Shih, Francisca Vazquez, Aviad Tsherniak, Alison M. Taylor, Jin Zhou, Zhong Wu, Ashton C. Berger, Marios Giannakis, William C. Hahn, Andrew D. Cherniack and Matthew Meyerson
    Cancer Discov January 1 2018 8 (1) 108-125; DOI:10.1158/2159-8290.CD-17-0532

    Varied noncoding and coding alterations observed across multiple cancer types converge to increase KLF5 activity and create a potential therapeutic vulnerability.

News in Brief

Research Watch

Back to top

Jump to

Advertisement